We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High NT-proBNP Paradoxically Shows Lower Risk in Early Pregnancy

By LabMedica International staff writers
Posted on 03 Feb 2022
Print article
Image: Elecsys Pro-BNP II Gen Assay may identify higher natriuretic peptide levels during early pregnancy were better for maternal blood pressure (Photo courtesy of Biolab Diagnostics)
Image: Elecsys Pro-BNP II Gen Assay may identify higher natriuretic peptide levels during early pregnancy were better for maternal blood pressure (Photo courtesy of Biolab Diagnostics)
Hypertensive disorders of pregnancy are associated with future cardiovascular disease, perhaps because of subclinical cardiac dysfunction before pregnancy leading to impaired adaptation to pregnancy.

N-terminal pro-brain natriuretic peptide (NT‐proBNP) is emerging as a diagnostic tool in the diagnosis of heart failure. It increases with ventricular volume expansion and pressure overload. It is raised in several cardiac conditions, but most studies have focused predominantly on systolic dysfunction in comparatively young patients.

Clinical Scientists at the University of Pittsburgh School of Medicine (Pittsburgh, PA, USA) and their colleagues investigated whether higher concentrations NT-proBNP in early pregnancy would be associated with hypertensive disorders of pregnancy and hypertension 2 to 7 years post-partum. A total of 4,103 nulliparous women with complete data and no pre-pregnancy hypertension or diabetes, who were treated at eight clinical sites, were included in a study. Women were followed up with for 2 to 7 years after pregnancy. Data were collected from October 2010 to October 2017, and data were analyzed from August 2020 to November 2021. NT-proBNP concentrations were measured using an electrochemiluminescence immunoassay from a first-trimester blood sample.

The scientists reported the mean ± SD age of the study participants was 27.0 ±5.6 years. Among these women, 909 (22.2%) had an adverse pregnancy outcome, and 817 (19.9%) had hypertension at the follow-up visit. Higher NT-proBNP concentrations were associated with a lower risk of hypertensive disorders of pregnancy (adjusted odds ratio per doubling, 0.81; 95% CI, 0.73-0.91), which persisted after adjustment for age, self-reported race and ethnicity, early-pregnancy body mass index, smoking, and aspirin use. Similarly, higher NT-proBNP concentration in early pregnancy was also associated with a lower risk of incident hypertension 2 to 7 years after delivery; adjusted odds ratio per doubling, 0.84, an association that persisted after controlling for confounders, including hypertensive disorders of pregnancy.

Alisse K. Hauspurg, MD, an obstetrician-gynecologist and lead author of the study, said, “Women who experienced adverse pregnancy outcomes had lower first-trimester concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), median 56.0 pg/mL, a biomarker for subclinical cardiac dysfunction, versus 63.0 pg/mL for women who did not have these outcomes.”

The authors concluded that in this cohort study, higher NT-proBNP concentrations in early pregnancy were associated with a lower risk of hypertensive disorders of pregnancy and hypertension 2 to 7 years post-partum. These findings suggest that normal early-pregnancy cardiovascular physiology, as assessed by NT-proBNP concentration, may provide biologic insights into both pregnancy outcome and cardiovascular disease risk. The study was published on January 19, 2022 in the journal JAMA Cardiology.

Related Links:
University of Pittsburgh School of Medicine

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.